Caribou Biosciences, Inc. SEC Filings

CRBU NASDAQ

Welcome to our dedicated page for Caribou Biosciences SEC filings (Ticker: CRBU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Trying to track every genome-editing breakthrough Caribou Biosciences reports while deciphering 200-page SEC documents? Early-stage biotech filings are dense with trial data, CRISPR patent updates, and cash-runway details that move the stock overnight.

Stock Titan turns those complexities into clarity. Our AI reads each Caribou Biosciences annual report 10-K simplified, flags R&D spend trends, and highlights chRDNA milestones so you can focus on what drives valuation. Need the latest Caribou Biosciences quarterly earnings report 10-Q filing? You’ll get real-time alerts plus an AI summary that connects lab progress to financial burn.

Looking for insider sentiment? Instantly scan Caribou Biosciences Form 4 insider transactions real-time to see when executives buy after positive CB-010 data. Our coverage also answers common searches such as “Caribou Biosciences insider trading Form 4 transactions”, “Caribou Biosciences proxy statement executive compensation”, and “Caribou Biosciences 8-K material events explained.”

AI-powered summaries strip the jargon from clinical-trial risk factors—perfect for understanding Caribou Biosciences SEC filings explained simply.
Real-time EDGAR feeds ensure you never miss an 8-K announcing dose-expansion data.
Expert context connects share-based compensation shifts to dilution risk in one click.

Whether you’re modeling cash needs, comparing CAR-T pipelines, or understanding Caribou Biosciences SEC documents with AI, Stock Titan delivers the Caribou Biosciences earnings report filing analysis you need—without the endless page-scrolling.

06/23/2025 08:02 AM

Filing

[8-K] Caribou Biosciences, Inc. Reports Material Event

Rhea-AI Summary

Schedule 13G filing summary for Ostin Technology Group Co., Ltd. (NASDAQ: OST)

The filing, dated 30 June 2025, discloses that three related reporting persons — Streeterville Capital LLC, Streeterville Management LLC, and John M. Fife — have acquired an aggregate of 10,500,000 Class A Ordinary Shares of the issuer. The holding represents 9.8 % of OST’s outstanding Class A shares, based on 107,430,032 shares outstanding as of 12 May 2025.

All shares are held with sole voting and sole dispositive power; there is no shared voting or dispositive authority indicated. The shares are beneficially owned directly by Streeterville Capital LLC and indirectly by the other two filers. The parties filed under Schedule 13G, certifying the stake was not acquired to change or influence control of the issuer, which signals a passive investment posture rather than an activist agenda.

Key filing details:

CUSIP: G67927114
Issuer HQ: Nanjing, Jiangsu, China
Reporting Persons’ HQ: 303 E Wacker Dr., Suite 1040, Chicago, IL 60601
Citizenship: Streeterville entities — Utah, USA; John M. Fife — United States

No additional transactions, derivative positions, or intent to form a group were disclosed. The certification affirms the investment is not for control purposes, and there are no indications of plans that could materially alter OST’s governance or capital structure.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

FAQ

What is the current stock price of Caribou Biosciences (CRBU)?

The current stock price of Caribou Biosciences (CRBU) is $1.26 as of June 30, 2025.

What is the market cap of Caribou Biosciences (CRBU)?

The market cap of Caribou Biosciences (CRBU) is approximately 122.8M.

What is Caribou Biosciences’ primary focus?

Caribou Biosciences focuses on developing clinical-stage, off-the-shelf CAR-T cell therapies using advanced CRISPR genome editing, primarily addressing oncology and autoimmune diseases.

How does Caribou differentiate its CRISPR platform?

The company uses a proprietary CRISPR hybrid RNA-DNA (chRDNA) platform, which enhances precision, reduces off-target effects, and enables complex gene modifications such as PD-1 knockouts and partial HLA matching.

What therapeutic areas are targeted by its product candidates?

Caribou’s pipeline includes therapies for hematologic malignancies like B cell non-Hodgkin lymphoma, multiple myeloma, and acute myeloid leukemia, as well as autoimmune conditions such as lupus.

What are the key candidates in Caribou’s pipeline?

The company’s notable candidates include CB-010 for B cell malignancies and lupus, CB-011 for multiple myeloma, and CB-012 for acute myeloid leukemia, all leveraging advanced genome editing.

How does the allogeneic CAR-T approach benefit patients?

Off-the-shelf allogeneic CAR-T therapies enable quicker availability compared to autologous treatments, potentially reducing wait times and manufacturing complexities while ensuring uniform product quality.

What role does partial HLA matching play in their strategy?

Partial HLA matching is implemented to enhance therapy persistence and efficacy by reducing immune rejection, making the allogeneic cell therapy more adaptable across a diverse patient population.

How does Caribou generate revenue?

Revenue is generated through licensing agreements, strategic collaborations, and the advancement of its clinical-stage cell therapy programs, rather than through direct product sales at this stage.

What insights does their clinical pipeline provide about their market position?

The diversified pipeline targeting both cancer and autoimmune diseases, combined with the precision of their CRISPR platform, positions Caribou as an innovative player in the evolving biopharmaceutical landscape.